OTC:CPMD
CANNAPHARMARX, INC.
A capitalizing cannabis pharmaceutical firm navigating severe liquidity constraints and deep operational losses while attempting to scale production capabilities.
Key Metrics
Investment Thesis
Bull Case
If the company can successfully secure new capital markets or strategic partnerships to address its liquidity hole, there is high asymmetric upside potential given the low absolute equity value and strong regulatory tailwinds in the cannabis sector. The zero capital expenditures suggest an asset-light pivot or a halt in growth spending that could preserve remaining cash reserves for debt restructuring. Market sentiment around medical cannabis continues to normalize, potentially unlocking valuation re-rating if profitability milestones are eventually achieved.
Bear Case
The investment case is severely compromised by negative shareholders' equity of $-19.8M and a cash balance of only $2,156 against massive interest obligations of $2.3M, creating an imminent default risk scenario. Operating revenue of merely $820k is insufficient to cover the cost of revenue of $3.8M, indicating severe margin collapse or accounting complexities that threaten solvency. Without a viable path to positive cash flow from operations within the next 12 months, bankruptcy proceedings are a distinct possibility for this OTC-traded entity.
About CANNAPHARMARX, INC.
Cannapharmarx, Inc. (CPMD) operates within the cannabis and pharmaceutical sectors, focusing on the development, production, and distribution of medical-grade cannabinoid products. The company serves markets seeking therapeutic solutions for chronic pain and inflammation through its specialized product lines. Current financials reflect a capital-intensive growth phase with significant operating losses typical of early-stage biotech or specialty manufacturing ventures.
Analysis
Management Discussion
The company reported a significant operating loss of $-3.6M and a net profit deficit of $-9.9M for the latest period, exacerbating its substantial retained earnings deficit of $-101.2M. Cash flow from operations turned negative at $-1.7M while financing activities provided only $1.7M, resulting in minimal cash balance growth despite zero capital expenditures. The financial structure shows a precarious working capital position with current liabilities nearly 26 times greater than current assets.
Industry Overview
The global cannabis industry is transitioning from prohibition to a multi-billion dollar therapeutic market driven by legalization trends and robust clinical research validating medical applications. Companies in this space face unique challenges including high regulatory compliance costs, complex supply chains, and the need for significant capital expenditure to build cultivation and processing facilities. Success in this sector increasingly depends on demonstrating pharmaceutical-grade quality control and securing long-term contracts with healthcare providers.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2024 |
|---|---|---|
| Revenue | $0 | $820.1K |
| Cost of Revenue | $0 | $3.8M |
| Gross Profit | $0 | $-2.9M |
| Operating Expenses | $5.2M | $671.3K |
| Operating Income | $-5.2M | $-3.6M |
| G&A | $2.2M | $116.6K |
| Stock-Based Comp | $181.0K | — |
| D&A | $294.9K | $0 |
| Depreciation | $12.8K | — |
| Other OpEx | $3.0M | $554.7K |
| Non-Operating Income | $-3.3M | $0 |
| Interest Expense | $2.3M | $2.3M |
| Pre-Tax Income | $-8.5M | $-3.6M |
| Income Tax | $0 | $0 |
| Continuing Ops | $-8.5M | $-3.6M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-8.5M | $-9.9M |
| Minority Interest | $0 | $0 |
| Net to Common | $-8.5M | $-9.9M |
| Metric | 2022 | 2024 |
|---|---|---|
| Current Assets | $100.0K | $1.0M |
| Cash & Equivalents | $2.3K | $2.2K |
| Inventory | — | $996.2K |
| Other Current Assets | $97.7K | $20.5K |
| Long-Term Assets | $5.3M | $9.8M |
| PP&E (Net) | $107.8K | $137.2K |
| Operating Leases | — | $5.2M |
| Other LT Assets | $5.2M | $4.5M |
| Total Assets | $5.4M | $10.8M |
| Current Liabilities | $17.2M | $25.8M |
| Accounts Payable | $6.9M | $4.8M |
| Other Current Liab | $10.3M | $16.7M |
| Long-Term Liabilities | $5.6M | $4.9M |
| Total Liabilities | $22.8M | $30.6M |
| Shareholders' Equity | $-17.3M | $-19.8M |
| Paid-In Capital | $74.5M | $80.1M |
| Retained Earnings | $-94.7M | $-101.2M |
| AOCI | $240.4K | $555.6K |
| Treasury Stock | $13 | — |
| Total L&E | $5.4M | $10.8M |
| Metric | 2022 | 2024 |
|---|---|---|
| Net Income (CFO) | $-8.5M | $-9.9M |
| Non-Cash Adjustments | $5.4M | $7.2M |
| Working Capital Changes | $1.7M | $1.0M |
| Cash from Operations | $-1.4M | $-1.7M |
| Capital Expenditures | — | $0 |
| Cash from Investing | $-116.0K | $0 |
| Debt Issuances | $913.0K | $363.4K |
| Cash from Financing | $1.4M | $1.7M |
| FX Effect | $134.2K | $0 |
| Net Change in Cash | $-25.4K | $1.5K |
| Beginning Cash | $27.8K | $650 |
| Ending Cash | $2.3K | $2.2K |
Frequently Asked Questions
How does CANNAPHARMARX, INC. make money?
Medical Cannabis Production, Pharmaceutical Cannabinoid Development, and Therapeutic Distribution Services
What are the main risks for CPMD?
Severe liquidity crisis indicated by $30.6M in liabilities versus only $1.0M in current assets, consistent multi-year net losses exceeding $9M annually, heavy reliance on external financing evidenced by high interest expenses of $2.3M, and the inherent regulatory volatility of the cannabis industry.
What is CPMD's competitive advantage?
Specialized formulation expertise in medical-grade cannabinoids, strategic positioning for emerging state-level legalization markets, and potential proprietary patent protections on key therapeutic compounds.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.